Introduction
Multiple sclerosis (MS) is a chronic-inflammatory disorder of the central nervous system leading to accumulating disability. Historically, myelin-directed, CD4
+, Th17
+ cells have been considered to be the important mediators of the inflammatory process [
1]. This is largely based on animal experimental autoimmune encephalitis models where T cell-mediated responses are key to pathogenesis [
2]. However, suppression of CD4
+, Th17
+ cells has only produced modest benefits in clinical trials in MS [
3,
4]. Therefore, other mechanisms may play a crucial role in the disease process.
Whilst animal models and in vitro studies in MS provide circumstantial evidence for the involvement of particular pathways, positive and properly conducted, negative trials provide invaluable information for understanding the cellular mechanisms that drive disease activity. Alemtuzumab, a CD52, T and B cell depleting antibody [
5], ocrelizumab, a CD20-B cell depleting antibody [
6] and cladribine, a lymphocyte depleting agent [
7], are immune-reconstitution therapies that are amongst the most efficacious treatments for MS and can provide long-term benefit from few treatment cycles [
4,
8,
9]. However, there is no clear consensus on their mode of action, particularly for cladribine [
7,
10].
It is well known that lymphocytes produce many secreted proteins, rapidly proliferate in response to infections and rely on both de novo and importantly salvage pathways for nucleotide synthesis. To accommodate this requirement, lymphocytes express high levels of adenosine deaminase (ADA) protein [
11,
12]. This prevents the accumulation of cytotoxic levels of deoxyadenosine triphosphate, by catalysing the deamination of adenosines to inosines [
12]. Cladribine is a chlorinated analogue of deoxyadenosine that is partially resistant to ADA [
12,
13]. This is phosphorylated by deoxycytidine kinase (DCK) to create lymphocyte cytotoxicity [
12]. This action is countered by cytosolic 5′ nucleotidase (5′NT) enzymatic activity that dephosphorylates phosphorylated-cladribine. Lymphocytes and lymphocytic cancers, including hairy cell leukaemia for which parenteral cladribine is licensed, have a high DCK-to-5′NT ratio relative to other cell types and are susceptible to cladribine-induced cytotoxicity [
12].
An oral-cladribine prodrug was shown to be very effective at controlling relapsing MS [
7,
8]. This was first licensed in 2011, but was later withdrawn when regulators requested more studies to address issues related to severe lymphopenia (25.6% (
n = 110/430) grade 3/4 found in year 2) and cancer seen in the pivotal trial [
7,
10]. However, we demonstrated that the short-term cancer risk of oral cladribine was no greater than for any of the licensed disease modifying treatments (DMT) [
14], and instigated a compassionate-use programme using generic, subcutaneous cladribine that was dose-adapted to limit severe lymphopenia [
15]. This and probably the licensing of alemtuzumab, which induces significantly more lymphopenia and side-effects than cladribine [
5,
7,
16], prompted re-submission of cladribine tablets to the regulators. These were licensed in Europe for the treatment of relapsing MS [
10].
Although, cladribine is considered to be a T and B cell inhibitor, emphasis has been placed on T cell inhibition as a mechanism of action [
10,
17]. However, immunophenotyping data demonstrated that effective doses of oral cladribine induced only about a 20–30% depletion of CD8
+ T cells and about a 40–45% depletion of CD4
+ T cells within 12 months that was reflected by comparable memory T cell depletion, but induced marked (80–85%) CD19
+ B cell depletion [
16]. Alemtuzumab induced a similar, but more transient depletion, of CD19
+ B cells [
18] again focussing attention towards the long-term depletion of T cells as a mechanism of action [
5]. However, analysis of CD19
+ subpopulations in alemtuzumab-treated people with MS (PwMS) demonstrated that it was a composite response of enhanced immature and mature B cell hyper-repopulation that masked a substantial and sustained depletion of memory B cells [
18]. Importantly, we identified that memory B cells were depleted by all DMT that inhibit MS, in a manner reflecting their efficacy in controlling relapsing MS [
4,
19]. We therefore hypothesised that given the high efficacy of cladribine [
7,
8], it too would deplete memory B cells and that public gene expression databases would contain data on purine salvage pathways genes that may explain its mechanism of action.
Discussion
Although memory B cells have previously been shown to be suppressed by alemtuzumab in MS, with numbers remaining low for at least 50 weeks post-therapy [
18], this action was extended here to show an effect on activated and both immunoglobulin class-switched and unswitched memory B cells. Importantly, to our knowledge this is the first evidence of the effect of cladribine on the memory B cell pool. These data support the hypothesis that memory B cells play an important role in the pathogenesis of MS [
4]. This data is consistent with the observation that agents that inhibit relapsing MS, with the exception of natalizumab that increases peripheral blood memory B cells presumably because they are prevented from entering the CNS, deplete peripheral memory B cells in a manner that appears to reflect their level of treatment efficacy [
4,
19]. Importantly, if memory cells are central to the action of DMT, that cladribine and alemtuzumab induced comparable memory B cell depletion, at least at about 1 year after treatment, indicates that the personalised, adaptive-dosing of generic cladribine can limit the occurrence and potential consequences of severe lymphopenia, possibly without a potential detriment to efficacy. However, serial monitoring of peripheral memory B cells will be required to determine the extent and longevity of the response. There is a lack of correlation of MS activity with the level of T cell subset deletion [
19]. Therefore, it will be of interest to determine whether peripheral blood memory B cell levels correlate with lesional/clinical activity, where CD8 T cells and memory B cells accumulate [
27], as seen in some other CD20-sensitive autoimmune conditions [
28‐
30].
The results obtained with alemtuzumab are comparable with results from the CARE-MS I study [
18]. It will be important to determine the extent of memory B cell depletion following oral cladribine use. However, it is anticipated that it may be similar to this study as comparable amounts of cladribine was administered based on the 40% bioavailability of the oral formulation compared to 100% bioavailability of the subcutaneous formulation used here [
31]. Indeed the level of lymphocyte, CD3 and CD19 T and B depletion by subcutaneous depletion observed here is similar with results of serial blood samples from the CLARITY oral-cladribine study [
16]. Although, we did not measure T cell subset depletion in this study, the level of CD3 depletion seen here (45.0% depletion in the mean number of CD3 cells in PwMS treated with cladribine at 44 weeks compared to controls) with subcutaneous cladribine was similar to that reported previously with 3.5 mg/kg oral cladribine (39.1 ± 2.4% depletion at week 44 from baseline), where the absolute number of CD4, CD45R0
+ memory T cells was depleted by 34.4 ± 6.3% (at 9 weeks) and 37.0 ± 2.9% (at 44 weeks) from baseline [
16] and CD8, CD45RO
+ memory T cells were depleted by only 15.2 ± 2.5% (at week 9) and 13.5 ± 6.3% (at week 44) from baseline. This may suggest that depletion of these T subsets by the dose of subcutaneous cladribine used here, may be limited also, but further studies are warranted to include analysis of Th1, Th17 cells and T regulatory cells to determine whether selective depletion occurs following cladribine. Indeed, by increasing the dose and frequency of dosing, more substantial depletion T cell, notably CD4 T cell depletion, can be achieved [
16,
17]. This may contribute to and even account for the clinical efficacy observed [
7,
8]. This study does not prove that memory B cells actually mediate an essential component of relapsing MS. Likewise, definitive proof that T cells are the central mediators of the action of DMT in MS in humans is circumstantial and unproven also and the levels of their peripheral blood depletion do not correlate with efficacy [
4,
16]. However, it is evident that DMT have a number of possible mechanisms of action [
4] and given the activity of CD20-depleting antibodies [
6], it is essential that the importance of B cells in disease control is considered.
The relatively high B cell expression levels of DCK, coupled with low levels of NT5C1 and ADA, compared to T cells, and neutrophils, and the higher turnover of B cells may create the B cell-selective depleting effect of cladribine seen in vivo [
16,
32]. This effect coupled with the slow kinetics of memory B cell repopulation [
18,
23], may explain why memory B populations are vulnerable to cladribine. As seen with other DMT including rituximab and alemtuzumab [
18,
24], the peripheral blood mature B cell population expands following depletion from the immature B cell pool that rapidly enter the blood, probably from the bone marrow [
18,
24]. This probably accounts for the apparent rapid normalisation of CD19
+ B cells that reconstitute the blood faster than T cells [
5,
16,
18]. It has been recently questioned whether fingolimod inhibits the action of alemtuzumab due to sequestration of immune cells within lymphoid tissue, probably the bone marrow, which may not be effectively purged by alemtuzumab [
33]. This could perhaps account for the rapid hyper-proliferation of immature and mature B cells seen after alemtuzumab treatment [
18]. The slower repopulation of B cells may reflect the fact that bone marrow, B cell precursor cells have deoxycytidine kinase and should therefore be sensitive to depletion by cladribine. Cladribine therefore behaves as a chemical CD19-depleter. In contrast to immature and mature cells, peripheral blood memory B cells repopulate very slowly from the lymphoid organ pool mostly via germinal centre activity [
34]. The germinal centres may be particularly vulnerable to inhibition by cladribine due to the high level of proliferation and DCK expression, leading to selective long-term loss of peripheral blood memory B cells. These may be depleted for 18 months or substantially longer in some individuals, as seen in development [
27] and following depletion with alemtuzumab or rituximab [
18,
28]. As the expression of DCK in plasma cells was low, it suggests that long-lived plasma cells may be relatively unaffected as occurs following CD20
+ B cell depletion, and thus not interfering with pre-existing vaccination responses. However, this remains to be established.
The longevity of the memory B cell depletion may be a key contributor to the mechanism of “induction therapy” activity of these pulsed immune-reconstitution treatments. Pathogenic memory cell repopulation may be a simple reason for treatment failures, requiring re-dosing, which occurs with cladribine and alemtuzumab [
5,
7‐
9]. Furthermore, it remains to be established whether the peripheral memory B cell compartment has value as a biomarker for response to disease activity, therapy and as an indicator for retreatment, as occurs in a number of other neurological and non-neurological, CD20 depletion-sensitive autoimmune conditions [
28‐
30].
Although we have placed emphasis on the potential role of the memory B cell, the thymus is targeted by cladribine [
35] and T cells still harbour elevated DCK levels, compared to other tissues, and are depleted. Furthermore, the action of cladribine may block the antigen presentation function of memory B cells and thus silence the remaining autoreactive T cells, using mechanisms suggested for CD20-depleting antibodies [
4]. Therefore, cladribine may control MS via an action on both T and B lymphocytes, notably as T cell activities are integrally involved in B cell function. However, the importance of memory B cells is consistent with the potential genetic and infectious aetiology of MS [
36]; the pathology that is associated with memory B cell accumulation during attacks [
27,
37], the generation of nerve and oligodendrocyte cytotoxic molecules and ectopic B cell follicle formation [
4,
27,
38]; and importantly the response to effective DMT [
4]. Epstein Barr Virus is believed to be an aetiological trigger of MS and drives the production of memory B cells, which may become relatively T cell-independent, and perhaps more autoimmune prone, due to B the antigen receptor and CD40-signalling mimics created by the virus [
36,
39].
The data presented here indicates that cladribine depletes memory B cells, in addition to T cells, and suggest that memory B cells could possibly be useful targets for the development of new, specific and better tolerated drugs for MS treatment. Also, in the shorter term, it is possible that we will be able to improve effectiveness and patient safety by routinely monitoring memory B cell levels. The oral and subcutaneous routes produce cladribine with defined pharmacokinetics that allow bioequivalent doses to be selected [
31]. Our subcutaneous cladribine protocol was originally developed for compassionate use for people without access to treatment, rather than an alternative to the commercial product. As such it has only been administered to PwMS from a few local centres within the UK. This may change as our experience becomes published and neurologists and nurses become comfortable using the oral formulation that has been licensed and is available for use in highly active relapsing MS within the UK and the rest of Europe [
10]. This could lead to the development of treatment options for all people with MS.